Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

4.03EUR
11:35am EDT
Change (% chg)

€0.03 (+0.75%)
Prev Close
€4.00
Open
€4.01
Day's High
€4.03
Day's Low
€3.96
Volume
77,498
Avg. Vol
116,711
52-wk High
€4.19
52-wk Low
€2.64

Select another date:

Thu, Mar 22 2018

BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros

* EXPECTS DOUBLE-DIGIT PRODUCT SALES GROWTH TO CONTINUE IN 2018

BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group‍​

* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP‍​

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15

* VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15

* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15

BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya

* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

Select another date: